Pfizer shares fell by 6.50% over the past month, accumulating a year-to-date loss of 11.31%. Over the past year, the stock decreased by 20.65%. The FDA's latest recommendation limits COVID-19 vaccine recommendations to seniors and individuals with specific medical conditions, potentially impacting Pfizer's revenue from its COVID franchise. Pfizer aims to stabilize in 2025, projecting FY 2025 revenues between $61 billion and $64 billion. The company's oncology sales are anticipated to increase due to several drugs in late-stage development, offsetting lagging COVID product revenue.
Shares of Pfizer (PFE) have lost 6.50% over the past month and are down 11.31% year-to-date. The share price has decreased 20.65% over the past year, falling over 35% in the last five years.
Pfizer's COVID-19 vaccines are now recommended primarily for seniors and select individuals with medical conditions, which may negatively impact the company's revenue from COVID-related products.
Despite strong sales for its COVID and non-COVID products in 2024, including Vyndaquel and Eliquis, Pfizer is trying to stabilize its financial outlook for 2025.
Pfizer forecasts total revenues for FY 2025 between $61 billion and $64 billion, with expectations that oncology sales will grow with several drugs in late-stage development.
Collection
[
|
...
]